Scarica l'app Stockscreener
1.68
0.60%
0.01
Pre-mercato:
1.69
0.01
+0.60%
Precedente Chiudi:
$1.67
Aprire:
$1.64
Volume 24 ore:
696.40K
Relative Volume:
0.77
Capitalizzazione di mercato:
$133.74M
Reddito:
$63.63M
Utile/perdita netta:
$10.62M
Rapporto P/E:
33.60
EPS:
0.05
Flusso di cassa netto:
$-8.64M
1 W Prestazione:
+15.07%
1M Prestazione:
-35.63%
6M Prestazione:
+3.07%
1 anno Prestazione:
+47.37%
Intervallo 1D:
$1.62
$1.69
Intervallo di 1 settimana:
$1.47
$1.73
Portata 52W:
$0.8214
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Nome
Protalix BioTherapeutics Inc.
Settore
Industria
Telefono
972 4 988 9488
Indirizzo
2 Snunit Street, Science Park PO Box 455, Karmiel
Confronta PLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
1.68 | 116.23M | 63.63M | 10.62M | -8.64M | 0.05 |
|
ONC
Beigene Ltd Adr
|
233.37 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.66 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.54 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.58 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-17 | Reiterato | Rodman & Renshaw | Buy |
| 2016-04-04 | Iniziato | Rodman & Renshaw | Buy |
| 2015-04-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2014-11-12 | Reiterato | R. F. Lafferty | Buy |
| 2014-01-24 | Iniziato | R. F. Lafferty | Buy |
| 2012-05-02 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Reiterato | Oppenheimer | Outperform |
| 2012-04-30 | Downgrade | Auriga | Buy → Hold |
| 2011-10-13 | Iniziato | Morgan Joseph | Hold |
| 2011-03-17 | Downgrade | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Reiterato | Oppenheimer | Outperform |
| 2010-10-14 | Reiterato | UBS | Buy |
| 2009-12-02 | Reiterato | Hapoalim | Outperform |
| 2009-09-22 | Iniziato | Canaccord Adams | Buy |
| 2009-09-02 | Iniziato | Hapoalim | Outperform |
| 2008-12-01 | Reiterato | Oppenheimer | Outperform |
| 2008-03-11 | Iniziato | UBS | Buy |
| 2007-11-20 | Iniziato | CIBC Wrld Mkts | Sector Outperform |
Mostra tutto
Protalix BioTherapeutics Inc. Borsa (PLX) Ultime notizie
What is Zacks Small Cap’s Estimate for PLX Q2 Earnings? - Defense World
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainw - GuruFocus
Protalix BioTherapeutics CFO to Present Latest Biotech Innovations at Exclusive Nasdaq Conference - Stock Titan
PLX: First Quarter Results - MSN
Protalix BioTherapeutics (NYSE:PLX) Lowered to Buy Rating by StockNews.com - Defense World
Protalix BioTherapeutics targets phase 2 launch for PRX-115 in H2 2025 - MSN
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call Transcript - Insider Monkey
Protalix: Q1 Earnings Snapshot - New Haven Register
Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlig - GuruFocus
Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ... By GuruFocus - Investing.com Canada
Earnings call transcript: Protalix Q1 2025 results miss forecasts, stock plunges - Investing.com
Protalix BioTherapeutics Reports Strong Q1 2025 Growth - TipRanks
Protalix BioTherapeutics (PLX) Sees Revenue Surge Amid Pipeline Advancements - GuruFocus
Small cap wrap: Protalix Biotherapeutics, Delivra Health, HIVE Digital, U.S. Global Investors... - Proactive financial news
Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Protalix eyes Phase II gout trial later this year following solid Q1 revenue growth - Proactive financial news
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results | PLX Stock News - GuruFocus
Protalix BioTherapeutics Inc Reports Q1 2025 Earnings: Revenue at $10.1M, Missing Estimates; EPS at -$0.05, Below Expectations - GuruFocus
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results - PR Newswire
Market Insight: Protalix BioTherapeutics Inc (PLX)’s Notable Drop, Closing at 2.73 - DWinneX
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025 - The Malaysian Reserve
Protalix BioTherapeutics to Announce First Quarter 2025 Financia - GuruFocus
Protalix Earnings: Biotech Pioneer to Present Q1 2025 Results and Pipeline Updates May 9 - Stock Titan
Contrasting Genocea Biosciences (NASDAQ:GNCA) & Protalix BioTherapeutics (NYSE:PLX) - Defense World
Can you still get a good price for Protalix BioTherapeutics Inc (PLX) Shares at this point? - uspostnews.com
Fabry Disease Treatment Market Deep Research 2025-2032 | Idorsia Pharmaceuticals Ltd., Protalix BioTherapeutics - openPR.com
HC Wainwright Has Bullish Forecast for PLX Q1 Earnings - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Protalix BioTherapeutics Inc (PLX) - Sete News
Protalix stock soars to 52-week high, hits $3.04 - Investing.com
Protalix stock soars to 52-week high, hits $3.04 By Investing.com - Investing.com India
Monitoring Protalix BioTherapeutics Inc (PLX) after recent insider movements - knoxdaily.com
Protalix BioTherapeutics (PLX) Plans $100 Million Securities Off - GuruFocus
Fabry Disease Market: Epidemiology, Drugs, Companies, DelveInsight | Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeuti - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
PLX’s earnings estimates: Are they on track to meet expectations? - uspostnews.com
Protalix BioTherapeutics Inc Inc. (PLX) Price Performance: A Technical Analysis Perspective - investchronicle.com
Protalix CFO Eyal Rubin to resign in six months By Investing.com - Investing.com India
Protalix BioTherapeutics' CFO Rubin to Leave - MarketWatch
Protalix stock soars to 52-week high, hits $2.76 By Investing.com - Investing.com South Africa
Eyal Rubin Resigns As CFO Of Protalix BiotherapeuticsSEC Filing - marketscreener.com
Protalix CFO Eyal Rubin to resign in six months - Investing.com
Protalix stock soars to 52-week high, hits $2.76 - Investing.com
The growth track for Protalix BioTherapeutics Inc (PLX) has changed recently - Sete News
Protalix BioTherapeutics Inc. Azioni (PLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):